 | |
| Clinical data | |
|---|---|
| Trade names | Hytrin, Zayasel, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a693046 |
| License data | |
| Routes of administration | By mouth |
| Drug class | α1 blocker |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 90–94% |
| Eliminationhalf-life | 12 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.118.191 |
| Chemical and physical data | |
| Formula | C19H25N5O4 |
| Molar mass | 387.440 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Terazosin, sold under the brand nameHytrin among others, is a medication used to treat symptoms of anenlarged prostate andhigh blood pressure.[1] For high blood pressure, it is a less preferred option.[1] It is taken by mouth.[1]
Common side effects includedizziness,headache, feeling tired, swelling,nausea, andlow blood pressure with standing.[1] Severe side effects may includepriapism andlow blood pressure.[1]Prostate cancer should be ruled out before starting treatment.[1] It is analpha-1 blocker and works by relaxingblood vessels and the opening of thebladder.[1]
Terazosin was patented in 1975 and came into medical use in 1985.[2] It is available as ageneric medication.[3] In 2023, it was the 217th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[4][5]
Reaction ofpiperazine with2-furoyl chloride followed bycatalytic hydrogenation of thefuran ring leads to2. This, when heated in the presence of 2-chloro-6,7-dimethoxyquinazolin-4-amine (1) undergoes direct alkylation to terazosin (3).
A 2022 study suggests that terazosin may have the potential to confer neuroprotection uponmotor neurons inmotor neuron disease, as a result of its ability to activatePGK1.[7]
